Gentilpasset behandling har siden begynnelsen av 2000-tallet blitt beskrevet som et av de nye, viktige våpnene som kan bekjempe kreft. Hør forsker Hege G. Russnes og professor Anne Hansen Ree, her fra Cancer Crosllinks i januar i år, fortelle om deres forskningsprosjekt MetAction, og hvordan de tar i bruk gentilpasset behandling for å gi et […]
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 328 entries.
Entries by oslocancer
Since 2009, The Cancer Registry of Norway has made use of health data in groundbreaking ways. They have taken the Nordic HPV vaccine program and turned it into a unique study using real world data. The project manager Mari Nygård hopes the study can inspire others to use health data in a similar ways and […]
Professor Vessela Kristensen is awarded King Olav V’s Prize for Cancer Research for her breast cancer research. A Prestigious Award The prize is one million NOK and will be presented to Kristensen by his Majesty King Harald V on behalf of the Norwegian Cancer Society, April the 16th. Kristensen is a Professor at the University […]
Kommentaren stod på trykk i Finansavisen 26.02.2018 og er skrevet av Ketil Widerberg, leder i Oslo Cancer Cluster og Nard Schreurs, direktør e-helse i IKT-Norge. Vi må snakke om hvordan vi skal forvalte våre helsedata før det er for sent. På jobb får vi betalt for det vi deler og gir av tid, kreativitet eller […]
Oslo Cancer Cluster member Photocure recently announced that the U.S. Food and Drug Administration (FDA) has accepted an expansion of the bladder cancer detection system “Cysview”. The FDA has accepted a supplemental New Drug Application (NDA) for “Cysview”. Photocure, the Norwegian company behind the drug-device system, has now been allowed to expand the system to […]
— We have succeeded in bringing more IT knowledge to the Biotech world, says Project Manager of PERMIDES D.B.R.K. Gupta Udatha. Merging IT and Biotech Together with five European clusters, Oslo Cancer Cluster have been managing a Horizon 2020 EU project “PERMIDES”. The cluster-to-cluster projects main goal was to stimulate collaboration between biotech companies […]
Entering 2018, Oslo Cancer Cluster welcomes four new members to the fold. Cellmover, Bryn Aarflot, Kuehne + Nagel and Mercuri Urval are our new cluster members. The Importance of Getting There Founded in 1890, Kuehne + Nagel operates from 9 locations in Norway, offering tailored logistics solutions for different industries, including for healthcare and […]
Inven2 are distributing start-up funds in Life Science! Very good news for Biotechs and cancer research companies in their early stages of development. Attention all Oslo Cancer Cluster and Incubator members. Inven2 received in late December 5 million NOK from Innovation Norway. They are now, subsequently, handing them out to Life science start-ups. Inven2 […]
For the tenth time the cancer experts gathered to share knowledge and ideas at Oslo Cancer Cluster Innovation Park. Cancer Crosslinks 2018 presented a diverse program covering themes from immuno-oncology to cachexia, to big data. Cancer research is changing rapidly. Immunotherapy and precision medicine has revolutionized cancer treatment. This year’s Cancer Crosslinks took a […]
Thursday January the 18th it’s time for the 10th Cancer Crosslinks here at Oslo Cancer Cluster Innovation Park. Hospital personnel, researchers and everybody interested get together for an update on – and to discuss – the latest within cancer research. This year’s conference will focus on Precision Treatment in cancer research with the headline: […]
Contact Team >
Oslo Cancer Cluster Incubator will support promising oncology biotechs to commercialize successfully.
The Incubator provides a dynamic, creative, and professional growth environment for scientists and start-ups.